The DOI matches its Crossref record.
Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F-18]-T807
Abstract
Aggregates of hyperphosphorylated tau (PHF-tau), such as neurofibrillary tangles, are linked to the degree of cognitive impairment in Alzheimer's disease. We have developed a novel PHF-tau targeting positron emission tomography imaging agent, [F-18]-T807, which may be useful for imaging Alzheimer's disease and other tauopathies. Here in, we describe the first human brain images with [F-18]-T807.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, at least one first-generation ligand has emerged as a reliable biomarker of 3R/4R PHF tau deposits [28].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [28]
In the citing paper
“18F-AV-1451 was originally developed to bind to paired helical filament tau in Alzheimer’s disease (Zhang et al., 2012; Chien et al., 2013; Xia et al., 2013), and has been extensively used in Alzheimer’s and non-Alzheimer’s diseases.”
From Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum (2020) · cites this paper as Chien et al., 2013
In the citing paper
“Imaging biomarkers for cortical tau have become available.19,20”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [19]
In the citing paper
“Flortaucipir is being developed as a PET tracer for detection of the aggregated tau of AD.19,21,22,23,24”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [19]
In the citing paper
“As expected, in vitro QC-01–175 and T807 displayed a significantly lower affinity for all recombinant immobilized tau forms than the reported KD of T807 for native, aggregated tau filaments from AD brain sections (KD15 nM)”
From Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models (2019) · cites this paper as Chien et al., 2013
In the citing paper
“However, small-molecule probes against tau oligomeric species, such as 18F-T807, have been developed and are currently in use as clinical tau PET tracers190.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [190]
Citations
Cited by
Sorted by citations
Items 601–653 of 653
Imagingof frontotemporal dementia
Rohrer, J. D. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781316091586.013
PET Imaging as a Diagnostic Tool in Alzheimer’s Disease
Rinne, J. O. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3560-4_13
Drzezga, A. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-30081-8_26
Imaging Approaches to Cerebral Cortex Pathology
Bartha, R., & Lee, T.-Y. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801942-9.00003-3
Tau PET Imaging for Dementia in Clinical Practice
Sugiyama, A., & Shimada, H. (2016) · RADIOISOTOPES · doi:10.3769/radioisotopes.65.517
Biomarkers of Alzheimer’s Disease
Saeed, U., Swardfager, W., Black, S. E., & Masellis, M. (2017) · Mental health and illness worldwide · doi:10.1007/978-981-10-0370-7_8-1
Imaging in Neurology Research III: Neurodegenerative Diseases
Endepols, H., & Neumaier, B. (2017) · Springer eBooks · doi:10.1007/978-3-319-42202-2_30
Tau PET in Neurodegenerative Diseases Manifesting Dementia
Okamura, N., Harada, R., Furumoto, S., & Kudo, Y. (2017) · Springer eBooks · doi:10.1007/978-4-431-55133-1_10
Sahara, N. (2018) · Folia Pharmacologica Japonica · doi:10.1254/fpj.152.4
Vasconcelos, I. C. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2018.tde-17042018-155058
Diagnostiek van de ziekte van Alzheimer
van der Flier, W. M. (2018) · Neuropraxis · doi:10.1007/s12474-018-00205-z
“Vanaf 2012 is ook tau-PET beschikbaar [32].”
Fact, Fiction, or Evolution: Mechanism Hypothesis of Alzheimer’s Disease
Pardo, J. V. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.83824
Shinohara, M., Hirokawa, J., Shimodaira, A., Tashiro, Y., Suzuki, K., Fukumori, A., Matsubara, T., Morishima, M., Saito, Y., Murayama, S., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-149164/v1
Progressive Supranuclear Palsy
Josephs, K. A. (2015) · Encyclopedia of Life Sciences · doi:10.1002/9780470015902.a0025798
Caprioglio, C., Garibotto, V., Jessen, F., Frölich, L., Allali, G., Assal, F., Frisoni, G. B., & Altomare, D. (2021) · Research Square · doi:10.21203/rs.3.rs-559570/v1
Longitudinal tau PET using [ 18 F]flortaucipir: Comparison of (semi)quantitative parametersPreprint
Visser, D., Tuncel, H., Ossenkoppele, R., Yaqub, M. M., Wolters, E. E., Timmers, T., Weltings, E., Coomans, E. M., den Hollander, M. E., van der Flier, W. M., et al. (2021) · medRxiv · doi:10.1101/2021.08.27.21262740
Qu’apporte l’imagerie hybride TEP-IRM dans l’étude des pathologies neuro-dégénératives ?
Idy-Peretti, I., Habert, M., & Kas, A. (2021) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2021.06.021 · Cited by 2
Tau Imaging in Neurodegenerative Dementia
Ponisio, M. R., Iranpour, P., & Benzinger, T. L. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-82367-2_12
Financial decision-making and capacity in older adults
Marson, D. C., Kerr, D. L., & McLaren, D. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816094-7.00020-9
Alkuraya, F. S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736847003.793566877
The Default Network of the Brain
Dijk, K. R. A. V., & Drzezga, A. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_7
Perani, D. (2013) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718113640.793484091
Pharmacological interventions in mild cognitive impairment and dementia
Hugon, J., & Paquet, C. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198701590.003.0128
Neuroimaging in Psychiatric Drug Development and Radioligand Development for New Targets
Takano, A., Halldin, C., & Farde, L. (2020) · Springer eBooks · doi:10.1007/978-3-030-57231-0_1
Misquitta, K., Rosen, H. J., & Tartaglia, M. C. (2016) · Cambridge University Press eBooks · doi:10.1017/9781139924771.004
Perani, D. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727195707.793537453
Perani, D. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.725773166.793537454
Pasquesoone, H., Vercouillie, J., Balageas, A., Gissot, V., Dupont, A.-C., Arlicot, N., Maia, S., Beaufils, É., & Ribeiro, M. J. (2022) · Médecine Nucléaire · doi:10.1016/j.mednuc.2022.05.001
Traits and Trammels of Tau Tracer Imaging
Villemagne, V. L., Lopresti, B. J., Doré, V., Minhas, D. S., Gogola, A., Nadkarni, N. K., Mason, N. S., Bourgeat, P., López, O. L., Ikonomović, M. D., et al. (2023) · Springer eBooks · doi:10.1007/978-3-031-35098-6_6 · Cited by 1
Zeydan, B., & Kantarci, K. (2023) · Springer eBooks · doi:10.1007/978-3-031-35098-6_1 · Cited by 2
Research trends in brain imaging of mild cognitive impairment in 25 years: a bibliometric analysis
Satyasari, D., & Rorong, A. T. W. (2023) · Universa Medicina · doi:10.18051/univmed.2023.v42.214-226
“The presence of biomarkers allows pre-symptomatic diagnosis and evaluation of disease progression.((7)) However, to determine how well these screening techniques and biomarkers can predict the risk in MCI individuals, further studies are needed in individuals with different levels of risk.”
BackgroundTargeting Various Pathogenic Pathways for the Development of Anti-alzheimer’s Drugs: An Update
Ambreen, S., Fatima, N., Umar, M., Shaququzzaman, M., Alam, M. M., & Ali, R. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266274924231002110733
(2000) · Time to knit · doi:10.1016/s0246-0378(14)62799-8
(2000) · Time to knit · doi:10.1016/s1879-8551(15)71672-6
Takahata, K., Moriguchi, S., Suzuki, H., Kurose, S., Momota, Y., Tagai, K., Endo, H., Kataoka, Y., Ichihashi, M., Komatsu, Y., et al. (2025) · Neuromethods · doi:10.1007/978-1-0716-4494-2_4
Central Nervous System Nuclear Imaging
Muhleman, M., Brown, R. K. J., Wong, K. K., Al-Dulaimi, R., & Bohnen, N. I. (2025) · Seminars in Roentgenology · doi:10.1053/j.ro.2025.04.006
Vavsari, V. F., Golmohammadi, F., & Balalaie, S. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837677139-00411
Mizraji, E., Lin, J., & Pomi, A. (2025) · BioEssays · doi:10.1002/bies.70032
“PET imaging has allowed visualization of the spatial distribution of β -amyloid plaques since the mid-2000s [51], but it was not until a decade later that neurofibrillary tangle pathology became selectively detected [52].”
Imaging Markers of Amyloid and Tau in Alzheimer Disease
Tarawneh, R. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_20
d'Orychymont, F., Tong, J., Kaplan, A. L., Shoichet, B. K., Mathis, C. A., Stehouwer, J. S., & Vasdev, N. (2025) · Canadian Journal of Chemistry · doi:10.1139/cjc-2025-0058
Nakayama, K., Nemoto, K., Endo, H., et al. (2025) · medRxiv · doi:10.1101/2025.10.08.25337562
Matsubara, K., Ibaraki, M., & Kinoshita, T. (2022) · Figshare · doi:10.6084/m9.figshare.20408898
Discovery of a novel tau PET tracer: Design, synthesis, radio-labeling, and preclinical evaluations
Yao, D., Zhang, N., Yao, Q., Xie, Y., Tian, R., Wu, X., & Kuang, W. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118542
Karim, F., Biju, A. P., Liang, C., Santos, C. J., Rajarethenam, M., & Mukherjee, J. (2026) · Research Square · doi:10.21203/rs.3.rs-8463304/v1
“[ 18 F]�ortaucipir (also known as T807) was among the �rst tau PET tracers to show promise in evaluations of clinical AD with its strong a�nity to tau aggregates [13, 35, 59].”
Tomadesso, C. (2018) · theses.fr (ABES) · doi:10.70675/7fad6418zff81z49c7z984dz63aa2e44d7fc
Joint Reconstruction of Longitudinal Positron Emission Tomography Studies for Tau Protein Imaging
Tiss, A. (2019) · theses.fr (ABES) · doi:10.70675/c487be06z4e17z48c0za864zfe62a434cd75
Abdelouahab, O. B. (2021) · theses.fr (ABES) · doi:10.70675/97f4885fz3f5cz4234zb8e2ze3fa7c4e3d41
Virtual histopathology of Alzheimer's disease
Chourrout, M. (2023) · theses.fr (ABES) · doi:10.70675/10f76dd7za946z404bzb78az3782a7ef9c69
Tau-mediated Mechanisms in Alzheimerʼs Disease Pathogenesis
Narayanappa, T. S., Ananthanarayana, V., & Chinnathambi, S. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06057-7
“…higher uptake in AD patients compared to healthy controls and showed a regional binding pattern consistent to Braak staging of NFT pathology [162, 163], while second-generation Tau-PET tracers like [ 18 F]-MK6240, [ 18 F]-RO948, and [ 18 F]-PI2620 show high selective affinity for AD-type NFTs…”
Lopes-Gomes, E., Resende, F. F. B., Greuel, A. M., Marina, C. L., de Sant’Ana, F. J. F., Titze-de-Almeida, S. S., & Titze‐de‐Almeida, R. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261491819
Metadata
- Authors
- Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C.
- Affiliations
- Siemens Molecular Imaging, Inc., Culver City, CA, USA
- University of California, Irvine (US)
- Hoag Memorial Hospital Presbyterian (US)
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2013-06-20
- Volume
- 34
- Issue
- 2
- Pages
- 457-468
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W4235092975
- Cited by
- 651
- References
- 0
- Citations by year
- 2026: 14 · 2025: 26 · 2024: 19 · 2023: 31 · 2022: 40 · 2021: 51 · 2020: 49 · 2019: 49 · 2018: 57 · 2017: 88 · 2016: 87 · 2015: 62 · 2014: 54 · 2013: 23
- FWCI
- 52.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- PHF-tau
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Carbolines, Female, Fluorine Radioisotopes, Frontal Lobe, Humans, Male, Middle Aged, Phosphorylation, tau Proteins, Early Diagnosis, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
